These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 9597116)
1. Different renal effects of two inhibitors of catechol-O-methylation in the rat: entacapone and CGP 28014. Hansell P; Odlind C; Männistö PT Acta Physiol Scand; 1998 Apr; 162(4):489-94. PubMed ID: 9597116 [TBL] [Abstract][Full Text] [Related]
2. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301 [TBL] [Abstract][Full Text] [Related]
4. Regulation of dopamine-induced natriuresisby the dopamine-metabolizing enzyme catechol-O-methyltransferase. Odlind C; Göransson V; Reenilä I; Hansell P Exp Nephrol; 1999; 7(4):314-22. PubMed ID: 10450019 [TBL] [Abstract][Full Text] [Related]
5. Changing dopaminergic activity through different pathways: consequences for renal sodium excretion, regional blood flow and oxygen tension in the rat. Odlind C; Fasching A; Liss P; Palm F; Hansell P Acta Physiol Scand; 2001 Jul; 172(3):219-26. PubMed ID: 11472309 [TBL] [Abstract][Full Text] [Related]
6. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. Törnwall M; Tuomainen P; Männistö PT Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912 [TBL] [Abstract][Full Text] [Related]
7. The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat. Odlind C; Reenilä I; Männistö PT; Ekblom J; Hansell P Pflugers Arch; 2001 Jul; 442(4):505-10. PubMed ID: 11510881 [TBL] [Abstract][Full Text] [Related]
8. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney. Sampaio-Maia B; Moreira-Rodrigues M; Pestana M Nephron Physiol; 2006; 103(1):p14-24. PubMed ID: 16352914 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
11. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Männistö PT; Tuomainen P; Tuominen RK Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144 [TBL] [Abstract][Full Text] [Related]
12. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Waldmeier PC; Baumann PA; Feldtrauer JJ; Hauser K; Bittiger H; Bischoff S; von Sprecher G Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):305-11. PubMed ID: 1980718 [TBL] [Abstract][Full Text] [Related]
13. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391 [TBL] [Abstract][Full Text] [Related]
15. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Forsberg MM; Huotari M; Savolainen J; Männistö PT Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340 [TBL] [Abstract][Full Text] [Related]
16. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis. Steulet AF; Stöcklin K; Wicki P; Waldmeier P Neurochem Res; 1993 Nov; 18(11):1131-6. PubMed ID: 8255364 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. Eklöf AC; Holtbäck U; Sundelöf M; Chen S; Aperia A Kidney Int; 1997 Sep; 52(3):742-7. PubMed ID: 9291195 [TBL] [Abstract][Full Text] [Related]
19. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. Brannan T; Prikhojan A; Yahr MD J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195 [TBL] [Abstract][Full Text] [Related]
20. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat. Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]